Can-Fite plans Phase IIb trial of namodenoson plus gemcitabine in advanced pancreatic cancerPUBT·2 days ago, 06:03 AMCANF+0.87%
Can-Fite says Phase III namodenoson trial in advanced liver cancer advances under FDA, EMA guidancePUBT·Aug 12 at 06:08 AMCANF+0.87%
Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe SyndromeUnusual Whales·Aug 3 at 06:03 AMCANF+0.87%
Can-Fite submits Phase 2 Lowe syndrome trial protocol for Piclidenoson to Italy hospitalPUBT·Aug 3 at 06:02 AMCANF+0.87%
Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic CancerUnusual Whales·Jul 14 at 06:04 AMCANF+0.87%
11 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga_article·Jul 2 at 12:05 PMLIMN-14.08%ELTX+0.64%
Biggest stock movers Thursday: FIZZ, CANF, and morebusinessinsider·Jul 2 at 04:30 AMEMBJ+0.87%FIZZ+1.97%
Can-Fite’s Namodenoson meets primary safety endpoints in Phase IIa trialWorldPharmaceuticals·Jul 2 at 04:22 AMCANF+0.87%
Top Biotech Gainers: CANF Climbs, RGNT Gears Up For Europe Launch, RNAZ, ELTX On Watchrttnews·Jul 1 at 10:22 PMCANF+0.87%ELTX+0.64%
Can-Fite BioPharma Soars 56% After Cancer Drug Trial Meets Safety EndpointUS Stock Market Update·Jul 1 at 03:12 PMCANF+0.87%
